Evidence map›Paper›PMID 34575305›Full record

ArticleJournal of clinical medicine2021

Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren's Syndrome.

Edyta Dziadkowiak, Agata Sebastian, Malgorzata Wieczorek, Anna Pokryszko-Dragan, Marta Madej, Marta Waliszewska-Prosół, Sławomir Budrewicz, Piotr Wiland, Maria Ejma

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edyta DziadkowiakDepartment of Neurology, Medical University of Wroclaw, 50-556 Wroclaw, Poland.ORCID 0000-0002-9618-9308
Agata SebastianDepartment of Rheumatology and Internal Medicine, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Malgorzata WieczorekDepartment of Geography and Regional Development, University of Wrocław, 50-137 Wroclaw, Poland.
Anna Pokryszko-DraganDepartment of Neurology, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Marta MadejDepartment of Rheumatology and Internal Medicine, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Marta Waliszewska-ProsółDepartment of Neurology, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Sławomir BudrewiczDepartment of Neurology, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Piotr WilandDepartment of Rheumatology and Internal Medicine, Medical University of Wroclaw, 50-556 Wroclaw, Poland.
Maria EjmaDepartment of Neurology, Medical University of Wroclaw, 50-556 Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decrease in the amplitude. The observed VEP deviations are not specific for specific diseases, but indicate disturbances in visual conductivity. VEP may play a diagnostic role in the early detection of visual involvement. The aim of the study was the functioning of visual pathway assessment on the basis of visual evoked potentials (VEP) examination, in patients with primary Sjögren's Syndrome (pSS), without focal symptoms of central nervous system disorder. The effect of disease activity, as assessed by clinical parameters and antibody levels (anti-Ro52, SSA, and SSB), on the central nervous system was also evaluated. Thirty-two consecutive patient with pSS (31 females, 1 male) were included in the study. VEP was performed at baseline, and after 6 (T6) years. Their results were compared longitudinally between the baseline and T6, depending on the duration of the disease and treatment. The immunological activity of pSS was also analyzed. The group of patients showed a significant prolongation of the P100 implicit time (105.5 ± 5.1 vs. 100.6 ± 3.9;

Indexed as

aching jointsanti-Ro52 antibodieshyperexcitability of cortexprimary Sjögren’s Syndromevisual evoked potentials

Identifiers

PMID34575305
PMCPMC8467284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.